Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
复制标题
DOI：
10.1056/nejm199604113341502
复制
发表时间：
1996-04-11
影响因子：
158.5
通讯作者：
Rainisio, M
中科院分区：
文献类型：
--
作者：
Maschio, G;Alberti, D;Rainisio, M
背景抑制血管紧张素转换酶的药物可减缓糖尿病肾病患者肾功能不全的进展。这些药物是否在其他肾脏疾病患者中具有类似的作用尚不清楚，我们进行了一项研究，以确定血管紧张素转换酶抑制剂苯那普利对各种潜在肾脏疾病患者肾功能不全进展的影响。在一项为期三年的试验中，583例因各种疾病引起的肾功能不全患者中，300例接受苯那普利治疗，283例接受安慰剂治疗，基础疾病包括肾小球病（192例），间质性肾炎（105例），肾硬化（97例），多囊肾（64例），糖尿病肾病（21例），和其他或未知疾病（104例），根据基线肌酐清除率对肾功能不全的严重程度进行分类：227例患者有轻度功能不全（肌酐清除率，46 - 60 mi/min），356例有中度功能不全（肌酐清除率，30 - 45 mi/min）。主要终点是基线血清肌酐浓度加倍或需要透析。三年后，苯那普利组31例患者和安慰剂组57例患者达到主要终点（P
Background. Drugs that inhibit angiotensin-converting enzyme slow the progression of renal insufficiency in patients with diabetic nephropathy. Whether these drugs have a similar action in patients with other renal diseases is not known, We conducted a study to determine the effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases.Methods. in a three-year trial involving 583 patients with renal insufficiency caused by various disorders, 300 patients received benazepril and 283 received placebo, The underlying diseases included glomerulopathies (in 192 patients), interstitial nephritis (in 105), nephrosclerosis (in 97), polycystic kidney disease (in 64), diabetic nephropathy (in 21), and miscellaneous or unknown disorders (in 104), The severity of renal insufficiency was classified according to the base-line creatinine clearance: 227 patients had mild insufficiency (creatinine clearance, 46 to 60 mi per minute), and 356 had moderate insufficiency (creatinine clearance, 30 to 45 mi per minute). The primary end point was a doubling of the base-line serum creatinine concentration or the need for dialysis.Results. At three years, 31 patients in the benazepril group and 57 in the placebo group had reached the primary end point (P